KLP Kapitalforvaltning
ARCT icon

KLP Kapitalforvaltning’s Arcturus Therapeutics ARCT Stock Holding History

KLP Kapitalforvaltning’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,200
Closed -$44.5K – 2194
2025
Q1 		$44.5K Hold
4,200
– – ﹤0.01% 2203
2024
Q4 		$71.3K Buy
+4,200
New +$79.1K ﹤0.01% 2188

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Schonfeld Strategic Advisors
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

KLP Kapitalforvaltning's ARCT Position: Q2 2025 in Review

KLP Kapitalforvaltning sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 4,200 shares — an estimated $44.5K sold.

KLP Kapitalforvaltning first reported a position in ARCT in Q4 2024 and held it in 2 quarters. The position peaked at $71.3K in Q4 2024. 144 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • KLP Kapitalforvaltning reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 4,200 Arcturus Therapeutics shares in Q2 2025, an estimated $44.5K.
  • KLP Kapitalforvaltning first reported a position in Arcturus Therapeutics in Q4 2024 and held it in 2 quarters.
  • KLP Kapitalforvaltning's Arcturus Therapeutics position peaked at $71.3K in Q4 2024.
  • 144 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2025, filed 23 Jul 2025.